MCM
ATRS

Moore Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Moore Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-140,000
Closed -$279K – 331
2017
Q4 		$279K Sell
140,000
-60,000
-30% -$131K 0.01% 243
2017
Q3 		$648K Hold
200,000
– – 0.01% 201
2017
Q2 		$644K Hold
200,000
– – 0.02% 170
2017
Q1 		$568K Buy
+200,000
New +$481K 0.02% 181

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's ATRS Position: Q1 2018 in Review

Moore Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q1 2018, closing a stake of 140,000 shares — an estimated $279K sold.

Moore Capital Management first reported a position in ATRS in Q1 2017 and held it in 4 quarters. The position peaked at $648K in Q3 2017. 102 funds tracked by Wall St. Rank hold ATRS as of Q1 2018.

  • Moore Capital Management reported no remaining Antares Pharma, Inc. position as of Q1 2018 after selling out during the quarter.
  • Moore Capital Management sold 140,000 Antares Pharma, Inc. shares in Q1 2018, an estimated $279K.
  • Moore Capital Management first reported a position in Antares Pharma, Inc. in Q1 2017 and held it in 4 quarters.
  • Moore Capital Management's Antares Pharma, Inc. position peaked at $648K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2018.

Based on Moore Capital Management's 13F filing for Q1 2018, filed 15 May 2018.